• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu

Vaccines

3/17/2008 Telecon 2 - Rotarix

MEMORANDUM

 

DATE: March 17, 2008
FROM: Laraine S. Henchal, Microbiologist Reviewer, DVRPA, CBER, Review Committee Chair, STN 125265/0
SUBJECT: Second telecon to discuss the the potency release specifications for STN #125265/0, Rotarix®, Rotavirus Vaccine, Live, Oral from GlaxoSmithKline Biologicals

This meeting was held to discuss GSK's March 7, 2008 response to the previous meeting held on February 29, 2008. The lot release potency specification now proposed by GSK is to release final product at a titer of ---------------------------------------------------------. End-of expiry titer is then stated as --------------------------- Requested dating period is -- months.

We don't consider the response to be satisfactory. It appears from what was submitted that the variability of the potency assay is actually around --- and not ---, which had been cited previously. The maximum titer at release should still not exceed the maximum titer that was studied in the clinical trials, therefore ----- should be the maximum for Iot release (thereby assuring with 95% confidence that the material's potency does not exceed --- given the --- variability). The lower end-of-expiry is harder to deal with due to the lack of data points. Does GSK have additional data on lots for stability? Yes, they do, but thought that they were only able to include stability for the actual lots used for the Phase 3 clinical studies. CBER replied that GSK can use any number of lots prepared with the same manufacturing process that will be licensed. GSK replied that they will have much more additional information to provide us on the stability in that case. CBER emphasized that the stability needs to be evaluated appropriately with statistical analysis of the regression line, slope and the standard error of the slope line. This will give us a better handle on the loss of potency over time. But it may be that the end expiry titer will be in the ----------- range.

GSK agreed to reconsider their specifications and will submit an additional data on the stability and a re-analysis of the data.

CBER participants:

Laraine Henchal
Steve Rosenthal
Paul Kitsutani
Jingyee Kou
Luba Vujcic
Phil Krause
Dino Feigelstock
Erik Henchal
Jerry Weir
Norman Baylor

GSK participants:

Leonard Friedland
Donna Boyce
Benedicte Dupasquier
Norris Pyle
Serge Debrus
Corine Lecomte
Isabelle Pierard
Jean-Claude Mareschal
Michael Vanderwerf
Isabelle Ernest
Michel Duchene
David Le-Tallec
Brigitte Cheuvart
Remon Abu-Elyazeed
Barbara Howe

 

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002